About this item:

207 Views | 148 Downloads

Author Notes:

Address for correspondence: Paul J. Marvar, PhD, Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Center for Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, 954 Gatewood Road Atlanta, GA 30329, pmarvar@emory.edu, (ph) 404-727-7739, (fax) 404-727-8070

All authors report no biomedical financial interests or potential conflicts of interest.

Subjects:

Research Funding:

This work was financially supported by The National Institutes of Health (K99 HL107675-01), (R01 MH096764) and the Burroughs Wellcome Foundation.

We thank the Emory University Biomarkers Yerkes Core supported by a National Primate Research Center Base Grant 2P51RR000165-51and Rodent Behavioral Cores for their contribution to this manuscript.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Neurosciences
  • Psychiatry
  • Neurosciences & Neurology
  • Angiotensin receptor type 1 (AT(1))
  • cardiovascular disease
  • fear memory
  • PTSD
  • renin-angiotensin
  • stress
  • POSTTRAUMATIC-STRESS-DISORDER
  • II-INDUCED HYPERTENSION
  • CARDIOVASCULAR-DISEASE
  • ALZHEIMERS-DISEASE
  • BED NUCLEUS
  • BRAIN
  • RATS
  • AMYGDALA
  • LOSARTAN
  • AVOIDANCE

Angiotensin Type 1 Receptor Inhibition Enhances the Extinction of Fear Memory

Tools:

Journal Title:

Biological Psychiatry

Volume:

Volume 75, Number 11

Publisher:

, Pages 864-872

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background The current effective treatment options for posttraumatic stress disorder (PTSD) are limited, and therefore the need to explore new treatment strategies is critical. Pharmacological inhibition of the renin-angiotensin system is a common approach to treat hypertension, and emerging evidence highlights the importance of this pathway in stress and anxiety. A recent clinical study from our laboratory provides evidence supporting a role for the renin-angiotensin system in the regulation of the stress response in patients diagnosed with PTSD. Methods With an animal model of PTSD and the selective angiotensin receptor type 1 (AT1) antagonist losartan, we investigated the acute and long-term effects of AT1 receptor inhibition on fear memory and baseline anxiety. After losartan treatment, we performed classical Pavlovian fear conditioning pairing auditory cues with footshocks and examined extinction behavior, gene expression changes in the brain, as well as neuroendocrine and cardiovascular responses. Results After cued fear conditioning, both acute and 2-week administration of losartan enhanced the consolidation of extinction memory but had no effect on fear acquisition, baseline anxiety, blood pressure, and neuroendocrine stress measures. Gene expression changes in the brain were also altered in mice treated with losartan for 2 weeks, in particular reduced amygdala AT1 receptor and bed nucleus of the stria terminalis c-Fos messenger RNA levels. Conclusions These data suggest that AT1 receptor antagonism enhances the extinction of fear memory and therefore might be a beneficial therapy for PTSD patients who have impairments in extinction of aversive memories.

Copyright information:

© 2014 Society of Biological Psychiatry.Published by Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote